Type 1 Multiple Endocrine Neoplasia Cohort Study

计划入组 2,000 人 · 首次发布于 2017 年 8 月 25 日

Study and Monitoring of Multiple Endocrine Neoplasia Type 1

计划入组 1,600 人 · 首次发布于 2019 年 5 月 29 日

Study and Follow-up of Multiple Endocrine Neoplasia Type 1

计划入组 2,000 人 · 首次发布于 2017 年 11 月 21 日

AMPK modulators (metabolic syndrome/type 2 diabetes/cancer)

Poliovirus type 2 antigen (formaldehyde inactivated)(Ipol, Kinrix, Pediarix, Pentacel, Quadracel, Vaxelis)

corticotropin releasing factor receptor-2 inhibitors (type 2 diabetes, metabolic syndrome)

Endocrine Research Society

Canada

ALPORT SYNDROME FOUNDATION

United States

International Rett Syndrome Foundation

United States

FDA Approves First Generic Liraglutide Injection for Type 2 Diabetes Treatment

Iranian Company Launches Spartina, Domestic Tirzepatide for Type 2 Diabetes and Obesity Treatment

Teva Launches First Generic GLP-1 Weight Loss Drug as FDA Approves Generic Saxenda